IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post-prophylaxis and late period

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00078388" target="_blank" >RIV/00023001:_____/19:00078388 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/19:10400437

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/pdf/10.1111/tid.13124" target="_blank" >https://onlinelibrary.wiley.com/doi/pdf/10.1111/tid.13124</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/tid.13124" target="_blank" >10.1111/tid.13124</a>

Jazyk výsledku

angličtina

Název v původním jazyce

IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post-prophylaxis and late period

Popis výsledku v původním jazyce

Background Cytomegalovirus (CMV) disease represents a serious complication in liver transplant (OLT) recipients. CMV prophylaxis reduces incidence of CMV disease in the early post-transplant period (on-prophylaxis disease, OPD) but may postpone its manifestation after the completion of prophylaxis. Post-prophylaxis disease (PPD) incidence after prophylaxis cessation may be modified by genetic factors. Methods We analyzed impact of IL28B rs1297986 variants on CMV disease incidence in 743 adult OLT recipients receiving universal prophylaxis. Results One hundred and forty-four (19.4%) patients had at least one CMV disease episode. One hundred and two of them (70.8%) had at least one OPD and 36 (25%) patients had PPD, six (4.2%) patients had both. The rate of IL28B T allele carriers was lower in PPD group (38.9%) in comparison with OPD group (66.7%, P = 0.005) and group without CMV disease (61.4%, P = 0.009). The impact of IL28B genotype on the risk of CMV OPD was significant neither in the allelic (TT + CT vs CC, P = 0.32) nor in the recessive model (TT vs CT + CC, P = 0.79). Contrarily, in the PPD group, T allele (TT + CT vs CC) had a protective effect, OR 0.4 (95% CI 0.2-0.8, P = 0.008). Further risk factors of PPD were age &lt;55 years and valganciclovir prophylaxis, whereas the risk factors of OPD were age &lt;55 years, cyclosporine A therapy and pre-transplant CMV serostatus (donor +/recipient -). Conclusions IL28B rs12979860 T allele carriers had a lower risk of CMV PPD.

Název v anglickém jazyce

IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post-prophylaxis and late period

Popis výsledku anglicky

Background Cytomegalovirus (CMV) disease represents a serious complication in liver transplant (OLT) recipients. CMV prophylaxis reduces incidence of CMV disease in the early post-transplant period (on-prophylaxis disease, OPD) but may postpone its manifestation after the completion of prophylaxis. Post-prophylaxis disease (PPD) incidence after prophylaxis cessation may be modified by genetic factors. Methods We analyzed impact of IL28B rs1297986 variants on CMV disease incidence in 743 adult OLT recipients receiving universal prophylaxis. Results One hundred and forty-four (19.4%) patients had at least one CMV disease episode. One hundred and two of them (70.8%) had at least one OPD and 36 (25%) patients had PPD, six (4.2%) patients had both. The rate of IL28B T allele carriers was lower in PPD group (38.9%) in comparison with OPD group (66.7%, P = 0.005) and group without CMV disease (61.4%, P = 0.009). The impact of IL28B genotype on the risk of CMV OPD was significant neither in the allelic (TT + CT vs CC, P = 0.32) nor in the recessive model (TT vs CT + CC, P = 0.79). Contrarily, in the PPD group, T allele (TT + CT vs CC) had a protective effect, OR 0.4 (95% CI 0.2-0.8, P = 0.008). Further risk factors of PPD were age &lt;55 years and valganciclovir prophylaxis, whereas the risk factors of OPD were age &lt;55 years, cyclosporine A therapy and pre-transplant CMV serostatus (donor +/recipient -). Conclusions IL28B rs12979860 T allele carriers had a lower risk of CMV PPD.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30213 - Transplantation

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Transplant infectious disease

ISSN

1398-2273

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

"art. no. e13124"

Kód UT WoS článku

000481577000023

EID výsledku v databázi Scopus

2-s2.0-85067470820